Cholera Vaccine
Brand names: Vaxchora · Active ingredient: Vibrio Cholerae Cvd 103-Hgr Strain Live Antigen
In short: VAXCHORA is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in persons 2 through 64 years of age traveling to cholera-affected areas. The effectiveness of VAXCHORA has not been established in persons living in cholera-affected areas.
What is Cholera Vaccine used for?
VAXCHORA is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in persons 2 through 64 years of age traveling to cholera-affected areas.
The effectiveness of VAXCHORA has not been established in persons living in cholera-affected areas.
The effectiveness of VAXCHORA has not been established in persons who have pre-existing immunity due to previous exposure to V. cholerae or receipt of a cholera vaccine.
VAXCHORA has not been shown to protect against disease caused by V. cholerae serogroup O139 or other non-O1 serogroups.
Cholera Vaccine dosage
For oral administration only.
Administer a single oral dose of VAXCHORA a minimum of 10 days before potential exposure to cholera.
The safety and effectiveness of revaccination with VAXCHORA have not been established.
Instruct recipients to avoid eating or drinking for 60 minutes before and after oral ingestion of VAXCHORA.
Prepare and administer VAXCHORA in a healthcare setting equipped to dispose of medical waste .
1.Remove the carton from the refrigerator . Locate the 2 packets: the buffer component (Packet 1) and the active component (Packet 2).
2.Pour 100 milliliters (mL) of cold or room temperature (41°F-72°F; 5°C-22°C) bottled water (purified, spring, or sparkling [carbonated]) into a clean, disposable cup. Do not use tap/faucet water, or any non-purified bottled water, other beverages, or liquids.
3.Use scissors to cut the top off the buffer component packet.
4.Empty buffer component packet contents into cup. Effervescence will occur.
5.Using a disposable stirrer, stir until the buffer component completely dissolves. For children 2 through 5 years of age, discard half of the buffer solution after mixing.
6.Use scissors to cut the top off the active component packet.
7.Empty the active component packet contents (lyophilized V. cholerae CVD 103-HgR) into the cup containing the buffer solution.
8.Stir for at least 30 seconds and until active component disperses to form a slightly cloudy suspension that may contain some white particulates.If desired, no more than 4 g (1 teaspoon) of sucrose (table sugar) or no more than 1 g (1/4 teaspoon) of non-flavored stevia sweeteners may be added and stirred into the suspension. Do not add any other sweeteners or medicinal flavorings as this can reduce the effectiveness of the vaccine.
9.Consume VAXCHORA within 30 minutes, if sucrose or non-flavored stevia are added. Consume VAXCHORA within 4 hours of reconstitution, if sucrose and non-flavored stevia have not been added, at room temperature around 70 °F (21°C). The recipient should drink the full contents of the cup. Some residue may remain in the cup and should be discarded with the cup.
NOTE: If the packets are reconstituted in the improper order, the vaccine must be discarded .
Dispose of the cup, packets, and stirrer according to standard procedures for medical waste.
Inactivate any spilled vaccine and clean any non-disposable equipment used in the preparation of VAXCHORA with 70% isopropyl alcohol or 10% bleach solution.
How to take Cholera Vaccine — instructions & advice from the label
Prior to administration of this vaccine, the health care professional should inform the individual of the following:
•Advise vaccine recipients to exercise caution regarding food and water consumed in cholera-affected areas, in accordance with the recommendations from the Centers for Disease Control and Prevention for the prevention of cholera in travelers.
•Educate vaccine recipients regarding the most common adverse reactions occurring within 7 days post-vaccination with VAXCHORA (tiredness, headache, abdominal pain, nausea/vomiting, lack of appetite, and diarrhea).
•Inform vaccine recipients that VAXCHORA is a live attenuated vaccine and has the potential for transmission of the vaccine strain to close contacts (e.g., household contacts). For at least 14 days following vaccination with VAXCHORA, vaccine recipients should wash their hands thoroughly after using the bathroom and before preparing or handling food.
•Instruct vaccine recipients to report adverse reactions to their healthcare provider.
VAXCHORA® is a registered trademark of Bavarian Nordic A/S
US License No. …
Warnings & precautions
Do not take this medicine if: Do not use in persons who have a history of severe allergic reaction (e.g., anaphylaxis) to any ingredient of VAXCHORA or to a previous dose of any cholera vaccine .
The safety and effectiveness of VAXCHORA have not been established in immunocompromised persons .
VAXCHORA may be shed in the stool of recipients for at least 7 days. There is a potential for transmission of the vaccine strain to non-vaccinated close contacts (e.g., household contacts) . Use caution when considering whether to administer VAXCHORA to individuals with immunocompromised close contacts.
Cholera Vaccine side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.
The most common adverse reactions for adults (incidence > 3%) were tiredness (31%), headache (29%), abdominal pain (19%), nausea/vomiting (18%), lack of appetite (17%) and diarrhea (4%).
The most common adverse reactions for children and adolescents (incidence ≥10%) were:
•Cohort 1 - age 12 to <18 years: headache (45%), tiredness (41%), abdominal pain (38%), lack of appetite (29%) and nausea (22%).
•Cohort 2 - age 6 to <12 years: tiredness (35%), abdominal pain (27%), headache (26%), lack of appetite (15%) and nausea (14%).
•Cohort 3 - age 2 to <6 years: tiredness (31%), lack of appetite (19%), and abdominal pain (17%).
Trials in Adults
The safety of VAXCHORA was evaluated in four randomized, placebo-controlled, multicenter clinical trials. A total of 3235 adults 18 through 64 years of age received one dose of VAXCHORA and 562 received placebo [physiologic saline (N=551) or lactose (N=11)]. Overall, the mean age was 32.5 years; 53.8% of trial participants were female; 67.1% were White, 27.3% were Black or African American, 1.8% were Asian, 1.7% were multiracial, 1.3% were other, 0.6% were American Indian or Alaskan Native and 0.3% were Native Hawaiian or Pacific Islander. …
Drug interactions
Avoid food or drink for 60 minutes before and after vaccine administration .
Vaccines
No data are available on concomitant administration of VAXCHORA with other vaccines.
Antibiotics
Avoid concomitant administration of VAXCHORA with systemic antibiotics since these agents may be active against the vaccine strain and prevent a sufficient degree of multiplication to occur in order to induce a protective immune response. Do not administer VAXCHORA to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.
Antimalarial Prophylaxis
Data from a study with a similar product indicate that the immune responses to VAXCHORA may be diminished when VAXCHORA is administered concomitantly with chloroquine. Administer VAXCHORA at least 10 days before beginning antimalarial prophylaxis with chloroquine.
Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to VAXCHORA .
About this medicine
VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR. CVD 103-HgR was constructed from the serogroup O1 classical Inaba strain 569B by deleting the catalytic domain sequence of both copies of the ctxA gene, which prevents the synthesis of active cholera toxin (CT). This attenuated strain remains able to synthesize the immunogenic non-toxic B subunit of CT (encoded by the ctxB gene). In addition, a marker was inserted into the hemolysin gene locus (hlyA) to enable differentiation of the vaccine strain from wild type V. cholerae O1.
The vaccine strain is grown in fermentors under controlled conditions in medium containing casamino acids, yeast extract, mineral salts, and an anti-foaming agent. The bacteria are concentrated by ultrafiltration before addition of a stabilization solution containing ascorbic acid (an antioxidant), Hy-Case SF (hydrolyzed casein [a protein derived from cow's milk], a cryoprotectant), and sucrose (a cryoprotectant). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 2d33d9ae-1fe6-477e-9285-8890f6e98be4. Read the full official label on DailyMed.